Rezvilutamide in metastatic, hormone-sensitive prostate cancer

Akhil P. Santhosh, Ajay Gogia

Open source

DOI: 10.4103/crst.crst_316_22
Published: 2023-01
Container: Cancer Research, Statistics, and Treatment
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.4103/crst.crst_316_22,
  title = {Rezvilutamide in metastatic, hormone-sensitive prostate cancer},
  author = {Akhil P. Santhosh and Ajay Gogia},
  year = {2023},
  journal = {Cancer Research, Statistics, and Treatment},
  doi = {10.4103/crst.crst_316_22},
  url = {https://doi.org/10.4103/crst.crst_316_22}
}

RIS

TY  - JOUR
TI  - Rezvilutamide in metastatic, hormone-sensitive prostate cancer
AU  - Akhil P. Santhosh
AU  - Ajay Gogia
PY  - 2023
JO  - Cancer Research, Statistics, and Treatment
DO  - 10.4103/crst.crst_316_22
UR  - https://doi.org/10.4103/crst.crst_316_22
ER  -

APA

Santhosh, A. P., & Gogia, A. (2023). Rezvilutamide in metastatic, hormone-sensitive prostate cancer. Cancer Research, Statistics, and Treatment. https://doi.org/10.4103/crst.crst_316_22

Source records

crossref · retrieved 2026-11-10T12:15:07.208Z